Mangoceuticals, Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
MGRX Nasdaq 2840 www.mangoceuticals.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mangoceuticals, Inc.

BC-Most Active Stocks - Mar 23rd, 2026 8:30 am
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. - Mar 17th, 2026 2:00 pm
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds - Mar 6th, 2026 2:00 pm
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study - Feb 23rd, 2026 2:05 pm
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program - Feb 19th, 2026 2:05 pm
Top Midday Decliners - Dec 19th, 2025 11:46 am
Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements - Dec 19th, 2025 8:38 am
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules - Dec 18th, 2025 6:30 am
Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim - Nov 14th, 2025 6:00 am
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs - Nov 13th, 2025 5:37 pm
Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management - Nov 13th, 2025 5:00 am